DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Claim Rejections - 35 USC § 112
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
Claims 2, 4, 6, 9, 12, 14, and 15 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention.
A broad range or limitation together with a narrow range or limitation that falls within the broad range or limitation (in the same claim) may be considered indefinite if the resulting claim does not clearly set forth the metes and bounds of the patent protection desired. See MPEP § 2173.05(c). In the present instance, claim 2 recites the broad recitation P1 and P2 are independently selected from the group consisting of acetyl, benzoyl, benzyloxycarbonyl, an fluorenylmethyloxycarbonyl, and the claim also recites “preferably, P1 and P2 are the same; further preferably, both P1 and P2 are acetyl” which is the narrower statement of the range/limitation. The claim(s) are considered indefinite because there is a question or doubt as to whether the feature introduced by such narrower language is (a) merely exemplary of the remainder of the claim, and therefore not required, or (b) a required feature of the claims.
Claim 4 recites the broad recitation, R is a C1-C6 alkyl or benzyl, and the claim also recites, “preferably selected from methyl, ethyl, isopropyl, tert-butyl and benzyl, more preferably methyl or ethyl”, which is the narrower statement of the range/limitation. Claim 4 also recites broad/narrow limitations of the palladium catalyst and the phosphine ligand.
Claim 6 recites the broad recitation, R is a C1-C6 alkyl or benzyl, and the claim also recites, “preferably selected from methyl, ethyl, isopropyl, tert-butyl and benzyl, more preferably methyl or ethyl”, which is the narrower statement of the range/limitation. Claim 6 also recites broad/narrow limitations for the acid used.
Claim 9 recites the broad recitation P1 and P2 are independently selected from the group consisting of acetyl, benzoyl, benzyloxycarbonyl, an fluorenylmethyloxycarbonyl, and the claim also recites “preferably, P1 and P2 are the same; further preferably, both P1 and P2 are acetyl” which is the narrower statement of the range/limitation. Claim 9 also recites that “preferably” R is selected from methyl, ethyl, isopropyl, tert-butyl and benzyl, more preferably methyl or ethyl.
Claim 12 recites the broad recitation P1 and P2 are independently selected from the group consisting of acetyl, benzoyl, benzyloxycarbonyl, and fluorenylmethyloxycarbonyl, and the claim also recites “more preferably, P1 and P2 are the same; further preferably, both P1 and P2 are acetyl” which is the narrower statement of the range/limitation.
Claims 14 and 15 are drawn to the use of the compound of formula V and the use of the compound of formula III for the preparation of compound I, campotothecins, and/or an antibody drug conjugate. However, the claims do not recite any positive method steps attributed to the production of compound I, thereby rendering the claims indefinite.
Claim Rejections - 35 USC § 101
35 U.S.C. 101 reads as follows:
Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.
Claims 14 and 15 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter. The claim(s) does/do not fall within at least one of the four categories of patent eligible subject matter because applicants claim the use of the compound of formula V and the use of the compound of formula III for the preparation of compound I, campotothecins, and/or an antibody drug conjugate. However, the claims do not recite any positive method steps attributed to the production of compound I.
Allowable Subject Matter
The following is a statement of reasons for the indication of allowable subject matter: claims 1, 3, 5, 7, 8, 10, 11, and 13 are drawn to a process for producing 5,8-diamino-3,4-dihydro-2H-1-naphthalenone, and to intermediate compounds that are not or fairly suggested by prior art.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to SIKARL A WITHERSPOON whose telephone number is (571)272-0649. The examiner can normally be reached M-F 9am-9pm IFP.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Scarlett Goon can be reached at 571-270-5241. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/SIKARL A WITHERSPOON/ Primary Examiner, Art Unit 1692